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Abstract 
Context: Some cancer patients experience pain and fatigue whereas some others experience 
only one of the two. Yet, it is not clear who experiences these unique patterns and why. 
Objectives: This study aimed to identify subgroups of cancer patients with unique pain and 
fatigue experiences in two different chemotherapy cycles, to examine how selected factors 
influenced subgroup membership, and identify how subgroups differed in concurrently 
measured functional-limitation outcome. 
Methods: The sample included 276 patients with diverse cancer types from four U.S. sites. 
To investigate subgroups, latent profile analyses were performed. Multinomial logistic 
regression and one-way analyses of variance type analyses were conducted to examine the 
influencing variables of subgroup membership and to examine differences among subgroups 
in patient outcome. 
Results: At both time points, the high-pain/high-fatigue and low-pain/low-fatigue subgroups 
were found. The low-pain/high-fatigue subgroup was present only in the first chemotherapy 
cycle. Pain and fatigue levels significantly differentiated subgroups at each time point (all 
p < .05). Across two time points, experiencing higher depressed mood increased the risk to be 
in the high-pain and high-fatigue subgroup (all p <.01). The high-pain and high-fatigue 
subgroup had the most serious limitations in activities (all p < .01). 
Conclusion: This study confirmed the existence of a unique symptom experience of pain and 
fatigue. This pattern should be acknowledged for symptom assessment and management. 
Key words: pain, fatigue, depressed mood, symptom cluster, symptom assessment, symptom 
management, cancer. 
Running Title: Unique Pain and Fatigue Experience 
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Introduction 
Managing and assessing pain and fatigue, both prevalent in cancer patients, are major 
priorities of oncology nursing research and practice.1 Of cancer patients, 70% suffer severe 
pain, requiring immediate intervention.2 Fatigue, prevalent in 60 to 90% of patients,3 can 
occur before diagnosis, during treatment, or years after treatment completion.4 Pain and 
fatigue are key symptoms that lower the quality of life for individuals with cancer.2,5 
Symptom-cluster researchers examine the co-occurring tendency of symptoms6 and 
often report that pain and fatigue tend to form a symptom cluster either alone or with other 
symptoms.7–9 However, several studies reported that pain and fatigue separately formed 
clusters with other symptoms,10,11 suggesting that pain and fatigue occur together only in a 
subgroup of cancer patients. 
Recent studies examining subgroups with respect to unique symptom experience also 
suggest that some cancer patients experience both pain and fatigue while some others 
experience only one of the two.12–15 For instance, a cross-sectional study examined subgroups 
with different symptom experience of pain, fatigue, depression, and sleep disturbance in a 
mixed sample of cancer patients.13 This study found that 15% of the sample experienced high 
intensity of all four symptoms; 15% experienced high intensity of pain and low intensity of 
fatigue; 35% experienced high fatigue and low pain; and 35% experienced low levels of all 
four symptoms. In another study, about 20% had only fatigue at four different time points 
after diagnosis while 23–45% experienced fatigue with pain and/or insomnia across all time 
points.15 
It is unclear who experiences both or only one symptom and what leads to their 
unique experience. This information helps delineate symptom management tailored to 
patients with a particular symptom experience. Previous studies included other symptoms 
such as insomnia, depressed mood, and cognitive disturbance, in addition to pain and fatigue, 
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to create subgroups.12–14 The inclusion of multiple symptoms in analyses could have 
hampered the examination of unique experiences concerning pain and fatigue as well as the 
influence of factors on the two symptoms. For example, the subgroups may have been created 
as a function of other symptoms, not of pain and fatigue only. Previous studies employed 
cluster analysis of subjects.12,13 The weakness of cluster analysis includes subjectivity in 
determining the number of subgroups; technical barriers in establishing replicability (i.e., 
reliability) of the final solution in the sample; and difficulty handling missing data. 
 The present study focused on only pain and fatigue in patients undergoing 
chemotherapy (CTX) in two selected time points. Our previous analysis12 found the 
subgroups with opposite directions of pain and fatigue in as discussed above and the present 
study further examined those subgroups with different data set and different approach. The 
treatment modality of CTX and radiation treatment both influence pain and fatigue 
experience.12,15,16 The present study focused on symptom experience during CTX cycles. The 
present study used latent profile analysis (LPA). LPA is a latent variable method and an 
extension of latent class analysis for continuous indicators. Using LPA, psychologists and 
sociologists examined subgroups with unique characteristics, such as substance-use 
behaviors17 or phenotypes of eating disorders.18 In LPA, subgroups are determined by a latent 
nominal variable and each subgroup has a unique profile of means and variances 
corresponding to specified indicator variables (i.e., fatigue and pain intensity in this study). 
The goals of LPA are often similar to those of cluster analysis.19 Yet, LPA solutions can be 
replicated and are statistically robust in selecting numbers of subgroups, especially in 
situations with non-normal distributions of indicators.20 
Age, disease stage, cancer type, and comorbid conditions may be associated with 
experiencing pain or fatigue.12,13,15,16 These variables were selected as influencing factors in 
the present study. Figure 1 shows variables categorized by the theory of unpleasant 
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symptoms,21 describing physiological, psychological, and situational factors. These factors 
influence symptom experiences that can lower performance. Depressed mood has been 
associated with fatigue and/or pain experience in many studies.12,13,22 In the present study, 
depressed mood is categorized as a psychological factor rather than symptom per se, because 
the present study planned to examine its influence on the pain and fatigue experience. 
The purposes of this study were (a) to identify the subgroups of cancer patients with 
unique experience of pain and fatigue at two CTX cycles, (b) to examine how selected factors 
influenced subgroup membership, and (c) to examine how subgroups differed in concurrently 
measured functional limitations. 
Methods 
Design 
This study employed a secondary analysis. The data were originally collected as a 
randomized clinical trial testing the effects of a cognitive behavioral intervention on fatigue 
and sleep in cancer patients undergoing CTX.23 The experimental group received education 
on energy-conservation strategies for fatigue and on sleep-enhancement strategies. The 
control group received general information on nutrition and diet for the equivalent time. A 
specially trained oncology nurse provided the intervention over the course of three interactive 
telephone sessions during the second, third, and fourth week after the first CTX treatment. 
Baseline data were collected at two time points: on Day 1 of the first CTX cycle 
before receiving treatment (Time 0) and on Day 4 after the first CTX treatment (Time 1). The 
follow-up time point (Time 2) was on Days 43–46 for patients on a weekly or 21-day 
regimen, or on Days 57–60 for those on a 14-day or 28-day regimen. The follow-up time 
point fell within 3 days of the most recent CTX treatment (after the 7th CTX for weekly 
cycles, the 3rd CTX for 21-day cycles, the 5th CTX for 14-day cycles, and the 3rd CTX for 
28-day cycles). Thus, Times 1 and 2 fell within 4 days of the most recent CTX. For the parent 
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study, the criteria for the post-CTX time points was based on the time points found to have 
maximal levels of symptoms after CTX (i.e., within 3 days of CTX).24,25 The present study 
only used symptom data collected at Time 1 and Time 2, since this study focused only on 
post-CTX symptom experience. 
Settings and Sample 
A convenience sample of oncology patients from four U.S. clinical sites were 
collected from 2004 to 2007: University of Utah, University of Cincinnati, Christiana 
Medical Center, and Fox Chase Cancer Center. Patients were at least 18 years of age; 
initiated a new CTX regimen with at least one drug administered intravenously in a cyclic 
manner; were diagnosed with lymphoma or breast, lung, colorectal, prostate, gynecologic, 
bladder, or testicular cancer; had no treatment other than surgery for at least one month 
before enrollment (concurrent radiation treatment allowed); and could read and understand 
spoken English. Patients were excluded with marrow or stem-cell transplantation, 
interleukins, interferon, or tumor-necrosis factor; chronic-fatigue disorder; sleep disorder; 
psychiatric disorder; anemia or depression during the prior 3 weeks; communication 
impairment; or enrollment in another psychoeducational intervention study. 
A total of 276 patients composed the final sample for analyses in both the parent and 
present study, consisting of an experimental group (n = 142) and a control group (n = 134). 
No additional inclusion or exclusion criteria were applied. Because the experimental 
intervention did not have a beneficial effect in reducing fatigue or sleep disturbance,23 both 
groups were combined and analyzed as a unit in the present study. However, the effect of 
experimental intervention on symptom experience at Time 2 was examined due to the 
possibility that it could be associated with subgroup creation. Missing data on the latent class 
indicators as well as covariates were handled by performing full information maximum 
likelihood estimation from complete raw data and thus, all data from the 276 patients were 
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used to estimate a model for this study. Because the data had already been collected, the 
sample size could not be changed. The findings were carefully interpreted according to the 
size and nature of the sample. 
Instruments 
Pain intensity was measured by the intensity subscale of the Brief Pain Inventory.26 It 
is composed of four items: the worst and least pain in the past 72 hours, average pain, and 
pain at the present moment. The scale ranged from 1 = no pain to 10 = pain as bad as you can 
imagine. Validity and reliability of this measure have been well established.26,27 Cronbach’s α 
was 0.88 in the present sample. 
The General Fatigue Scale (GFS), a fatigue measurement, was developed for the 
clinical assessment of cancer-related fatigue.28 The GFS consists of seven items that measure 
fatigue intensity, the level of distress caused by fatigue, and the impact of fatigue on daily 
activities in the present day, the past 48 hours, or the past week. The scale ranged from 1 = no 
fatigue to 10 = the greatest possible fatigue. Acceptable reliability and validity were 
reported.28 In the present study, Cronbach’s α was 0.92. 
The interference subscale of the Brief Pain Inventory measures interference with daily 
life caused by pain for the past 72 hours. The parent study modified this subscale to measure 
the interference due to symptoms, not specifically pain. The present study used this subscale 
as a functional-limitation measure. The subscale contains seven items that measure 
interference in general activity, life enjoyment, mood, relationships, sleep, walking, and work. 
The scale ranges from 0 = did not interfere to 10 = completely interfered. Cronbach’s α was 
0.91 in this sample. 
Depressed mood was measured by the depression subscale from the Profile of Mood 
States—Short Form.29 Validity and reliability were found to be acceptable in various 
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populations29 The depression subscale consists of five items on a Likert-type scale where 0 = 
not at all and 4 = extremely. Cronbach’s α was 0.90 in this sample.  
Analysis 
To identify subgroups, LPA with covariates was conducted at each data point, 
estimated in Mplus v.6.12. Models were evaluated based on Akaike’s information criterion, 
where smaller results were preferable;30 Bayesian information criterion, where a smaller 
number was preferable;31 the Bootstrap Likelihood Ratio Test, where the number of 
subgroups was tested against a smaller number of subgroups (p < 0.05 indicated that at least 
the present number of subgroups exist in the data); an entropy value higher than 0.8, which 
summarized the probability for the most likely latent class membership based on the 
estimated model; the interpretability of classes;20 and the model’s convergence on a stable 
solution. Where these criteria suggested different results, we subjectively assessed the 
preponderance of evidence. 
Interpretability was determined by distinguishability of subgroups in indicator 
variables, nontrivial subgroups sizes, and subgroup meaningfulness. Model convergence was 
examined through replication of maximum log-likelihood values across iterations, using 
random starting values. Distributions of the indicator variables were examined for extreme 
skewness and kurtosis. Pain had marked skewness and the model was estimated as if the 
given variable were normally distributed beyond its measured scale by using the censored 
command. 
Subgroup-membership influencing factors were examined by multinominal logistic 
regression predicting the latent nominal variable. Subgroup differences in functional 
limitation were examined using the limitations measure as an “auxiliary variable” associated 
with subgroup membership. This is analogous to a one–way analysis of variance (ANOVA) 
based on the identified subgroups, but minimizes measurement error in the predictor by using 
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subgroups as a latent variable. For missing data on subgroup indicators and covariates, we 
performed full-information maximum-likelihood estimation from complete raw data; thus, all 
data were used to estimate this study’s model. We obtained approvals from institutional 
review boards. 
Results 
Sample Nature 
Table 1 shows the demographic and clinical characteristics of the sample. Of note, 
55% were recruited from the comprehensive cancer center at Fox Chase. Patients were 
largely female, married, Caucasian, and had post-high school education. Half of the total 
sample had breast cancer and early stage cancer (Stages I and II). Half received symptom-
management intervention designed in the parent study. Approximately 90% were treated with 
CTX alone. The most frequent comorbid condition was hypertension (25%).  
Subgroups of Cancer Patients with Unique Pain and Fatigue Experience 
At Time 1, a model with three subgroups was selected based on the model selection 
criteria (see Table 2). Table 3 summarizes the mean values of symptom intensity for each 
subgroup. Pain was censored in the model estimation due to extreme skewness in distribution, 
so it carries no clinical meaning, but rather shows the relative distribution across subgroups. 
Subgroups were named based on pain and fatigue levels: high-pain/high-fatigue (HPHF; 
41.2%), low-pain/high-fatigue (LPHF; 34.3%), and low-pain/low-fatigue subgroups (LPLF; 
24.5%). According to the Wald tests, the subgroups differed from each other in both pain (all 
p < .0001) and fatigue intensity (all p < .05; see Table 3). 
The left panel of Figure 2 is a scatterplot of raw scores of respondents’ pain and 
fatigue at Time 1. Although in analytic models, subgroup membership is latent—respondents 
are never assigned to subgroups—points in the scatterplot are color coded by most likely 
subgroup membership of each respondent, to show the approximate loci of each subgroup. 
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Clinically, fatigue level was high in the HPHF subgroup; moderate in LPHF; and low in 
LPLF. Pain level was moderate in HPHF; low in LPLF; and was not measurably present in 
LPHF (see the left panel of Figure 2). Expected a posteriori classification based on the 
selected LPA model would have correctly classified 92% of HPHF, 93% of LPHF, and 88% 
of LPLF, corresponding to an entropy value of 0.80. 
At Time 2, a model with two subgroups was selected: HPHF (36.5%) and the LPLF 
(63.5%), graphically depicted in the right panel of Figure 2. Baseline model-testing statistics 
indicated the possibility of the three subgroups (see Table 2), appearing to be similar to the 
model at Time 1. However, the three-subgroup model was not selected due to the failure of 
parameter estimation for several variables and due to the fact that maximum log-likelihood 
value was not replicated, indicating convergence issue. Expected a posteriori classification 
based on the selected LPA model would have correctly classified 89% of LPLF, and 84% of 
HPHF, corresponding to an entropy value of 0.60. Although the low-entropy value was 
concerning in model selection, this two-subgroup model was best replicated using the 
maximum log likelihood value and was selected as the best model for Time 2. In the two-
subgroup model, pain and fatigue levels significantly differed, according to the Wald tests 
(all p < .001). HPHF had clinically moderate-to-high levels of pain and fatigue; LPLF had 
clinically low levels of pain and fatigue (see the right panel of Figure 2). 
Influencing Variables of Subgroup Memberships 
Multinomial logistic regression analyses were conducted with 10 variables at Time 1 
and 13 at Time 2 (see Table 4 for odds ratios). The three additional variables at Time 2 were 
the time lapse from the first CTX (i.e., 43–46 days vs. 57–60 days), symptom management 
intervention given by the parent study, and employment status. Employment status was 
included only because this variable had an interaction with intervention in the parent study. 
At Time 1, only depressed mood significantly influenced subgroup memberships. Patients 
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with higher depressed mood were more likely to be in HPHF (odds = 57.89, p < .0001) or 
LPHF (odds = 67.22, p < .0001), rather than LPLF.  
At Time 2, depressed mood was the most important predictor, showing similar 
tendencies as observed at Time 1. Patients with shorter time-lapses since first treatment (43–
46 days vs. 57–60 days) were less likely to be in HPHF (odd ratio = 0.14, p = .002). The 
comorbid condition of hypertension and arthritis were included in the model because they 
were the most prevalent. Patients with comorbid hypertension were more likely to be in 
HPHF (odds ratio = 5.29, p = .01).  
Subgroup Differences in Concurrently Measured Functional Limitation 
Although the subgroup-mean levels of functional limitations (i.e., 5.36 vs. 4.33 vs. 
1.49 at Time 1; 5.21 vs. 3.02 at Time 2) were moderate, statistically and clinically meaningful 
differences existed between subgroups (see Table 5). Patients in HPHF had the most serious 
functional limitations in both times (post hoc contrasts, all p < .01). At Time 1, functional 
limitation in LPHF was higher than in LPLF, but lower than in HPHF (post hoc contrasts, 
p < .01). 
Discussion 
LPA successfully identified subgroups with pain and fatigue that were replicable in a 
given sampling distribution. Two subgroups with the same direction of pain and fatigue 
intensity (HPHF and LPLF) are comparable to previous research findings on symptom 
clusters: pain and fatigue formed a symptom cluster in some cancer patients. HPHF had the 
most serious limitation in functional status. Thus, there is a clinical implication of a pain and 
fatigue cluster, supporting cumulative effects of multiple symptoms on functioning.12–14,32,33 
In addition, experiencing both pain and fatigue at a high intensity was independent of 
most selected situational and physiological variables. A higher level of depressed mood 
increased the risk to be HPHF, independent of other variables; depressed mood may be a 
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sentinel to detect subgroup with high pain and fatigue. Depressed mood did not differentiate 
between the two subgroups with high fatigue at Time 1, and is more closely associated with 
fatigue than pain. 
LPHF was found only at Time 1. The present study expected that patients with lower 
hemoglobin would fall into LPHF, but this was not supported. The effect of hemoglobin was 
inconclusive in this study due to limited variance and lack of control over the time lapsed 
since blood sampling. As shown in Figure 2, symptom patterns appear to be similar over two 
chemotherapy cycles with slightly more diversity at Time 2. However, LPHF was not 
separable from LPLF, possibly due to the very small number of subjects experiencing the 
LPHF pattern. Low pain and high fatigue experience may occur in patients with a particular 
condition during CTX, and the condition should be further examined. 
Previous studies reported 15–30% of participants with high pain and low fatigue.12,13 
It was expected that this subgroup would be associated with surgery, because surgery-site 
pain can occur without serious fatigue. However, the present study did not find this subgroup, 
and furthermore, did not find the surgery experience to influence the symptom experience. 
Considering that Time 1 was 4 days after the first CTX, both measurement time points 
consisted of long periods after surgery for most patients in this study. In Kim et al.,12 surgery 
experience predicted symptom experience only at the time point before CTX or radiation 
treatment. Given et al.16 reported that the pain and fatigue experience was influenced only 
when surgery was completed within 40 days. Surgery-related pain may occur without fatigue 
within a short period after surgery, may be different from pain with fatigue, and should be 
treated differently. Separating types of pain based on symptom experience may have 
important implications for symptom management. 
At Time 2, having a longer time-lapse from the first CTX and/or a comorbid 
condition of hypertension predicted a high pain and high fatigue experience. Although the 
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reason is not yet clear, the symptom experience could have been affected by medications for 
hypertension, not hypertension per se, and by various events that occurred after the first CTX 
(e.g., medications), not the time-lapse per se. 
LPA was recently used to examine an association between cytokines and a symptom 
cluster of pain, fatigue, sleep disturbance, and depression in a sample of cancer patients and 
their family caregivers.34 Their findings are not comparable to the present study findings 
because their subgroups were characterized by depression level, not by pain and fatigue level, 
due to the nature of the sample: their sample included family caregivers who may not 
experience serious pain and/or fatigue. Nonetheless, this particular study shows applicability 
of LPA to investigate a possible mechanism of symptoms. 
Limitations of this study include the use of many categorical variables, and cross-
sectional analysis of longitudinal data (i.e., separate analysis at each time point). Having too 
many categorical variables hampered analyses due to zero variance in cells of multiple 
categorical variables. Including more continuous variables, if possible, is recommended for 
future study in particular working with a small sample size. Also, measurement time points 
for influencing variables should be carefully selected to yield a clear conclusion. This study 
sample included patients undergoing concurrent treatments of CTX and RT. However, 
inclusion of those subjects would not influence on the study findings because the number is 
too small (n=18) and the measurement time point was set to capture symptom experience 
after CTX treatment. Using the longitudinal nature of the data, we are currently examined the 
transition patterns of patients in pain and fatigue experience over two different time points. 
Conclusion 
This study provides evidence of the existence of subgroups with unique pain and 
fatigue experiences in diverse cancer patients during CTX. Patients with both pain and 
fatigue at higher intensities had the worst patient outcomes, and tended to experience more 
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severe depressed mood. Clinicians need to pay special attention to this group of patients. 
Opposing directions of pain and fatigue experience appeared to exist only at a specific time 
point in the illness trajectory or with respect to patients with a particular cancer. Future 
studies should investigate the assessment/management strategies targeting pain or fatigue 
based on two main criteria: (a) the population where one can find a certain combination of 
pain and fatigue, and (b) the possible reasons behind unique pain and fatigue-symptom 
experience. 
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Figure 1. Statistical model of the study 
 
 
Note. athe direct influence of the hemoglobin level on fatigue was allowed in this statistical model but its effect 
was not tested. 
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Table 1. Demographic/Clinical Characteristics of the Sample (N = 276) 
 Variables Number of patients (%) 
Data collection site a Site A 152 (55.1) 
 Site B 87 (31.5) 
 Others 37 (13.4) 
Age (mean years ± SD)  53.97 (±11.79) 
Gender Female 228 (82.6) 
 Male 48 (17.4) 
Marital status Married 191 (69.2) 
 Single 81 (29.4) 
 Missing 4 (1.4) 
Race Caucasian 242 (87.7) 
 Non-Caucasian 30 (10.9) 
 Missing  4 (1.4) 
Education High school or less 70 (25.4) 
 Post-high school education 201 (72.8) 
 Missing  5 (1.8) 
Employment status Employed 150 (54.3) 
 Unemployed 122 (44.2) 
 Missing 4 (1.5) 
Study Group b Experimental group 142 (51.4) 
 Control group 134 (48.6) 
Cancer Type Breast 152 (55.1) 
 Lung 47 (17.0) 
 Gynaecologic cancer 32 (11.6) 
 Lymphoma 23 (8.3) 
 Others 22 (8.0) 
Disease stage Stage 1 44 (15.9) 
 Stage 2 90 (32.6) 
 Stage 3 68 (24.6) 
 Stage 4 44 (15.9) 
 Not staged  30 (10.9) 
Time lapse since the first CTX 43–46 vs.  159(57.6) 
 57–60 day  111(40.2) 
 Missing 6 (2.2) 
17 
 
 Variables Number of patients (%) 
Surgery right before baseline Yes 198 (71.7) 
 No 75 (27.2) 
 Missing 3 (1.1) 
Treatment modality during the study CTX only 250 (90.6) 
 Concurrent treatment with radiation treatment 18 (6.5) 
 Missing 8 (2.9) 
Comorbid conditions Hypertension 69 (25.0) 
 Arthritis 28 (10.1 ) 
Hemoglobin at Time 1  12.92 (±1.6) 
Hemoglobin at Time 2  11.75 (±1.6) 
Note. a Site A= Fox Chase Cancer Center, Site B= Utah. bThe primary study was a randomized clinical trial of 
the effectiveness of a cognitive-behavioral intervention on fatigue and insomnia. 
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Table 2. Comparisons of Models with Different Numbers of Subgroups at Each Time Point 
No. of 
classes 
Likelihood 
ratio G2 AIC 
BIC (sample 
size adjusted) 
Bootstrapped 
Likelihood 
Ratio Test  Entropy 
Time 1 
2 6211.67 6127.86 6149.44 0.0000  .75 
3 4537.80 6095.35 6123.67 0.01  .80 
4 4537.80 6077.32 6112.38 0.6  .84 
Time 2 
2 6646.84 6766.84 6793.81 0.000 .60 
3 4165.36 6729.39 6764.46 0.000 .73 
Note. Likelihood Ratio G2 is – 2 times of loglikelihood value; Smaller Akaike’s information criterion (AIC) is 
preferable; Smaller Bayesian information criterion (BIC) is preferable; p < 0.05 in Bootstrap Likelihood Ratio 
Test indicates that at least the present number of classes exist in given data; A higher than 0.8 entropy value (i.e., 
the summary of the latent class probability for most likely latent class membership based on the estimated 
model) is preferred. 
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Table 3. Subgroups of Pain and Fatigue Experience at Each Time Point  
(N = 276) 
Subgroups at Time 1 Mean (SD) 
Symptoms 
HPHF 
(n = 114, 41.2 %) 
LPHF 
(n = 90, 34.3 %) 
LPLF 
(n = 68, 24.5 %) 
Wald tests for 
pairwise comparisonsa 
(df = 1) 
Painb  3.91(1.65) -16.36(7.56) -0.07 (2.11) All p < .0001 
Fatigue 7.08(1.52) 6.26(1.59) 3.30(0.96) All p < .05 
Subgroups at Time 2 Mean (SD) 
Symptoms 
HPHF 
(n = 101, 36.5%)  
LPLF 
(n = 175, 63.5%) 
Wald test 
df = 1 
Painb 4.48 (1.52)  -0.82 (2.99) p < .0001 
Fatigue 6.59(1.96)  5.27 (1.78) p < .001 
Note: aBonferroni correction was done for multiple comparisons; bPain was censored and thus the value in this 
table does not carry clinical meaning but it shows relative distribution across groups; HPHF = high pain and 
high fatigue subgroup; LPLF = low pain and low fatigue subgroup; LPHF = low pain and high fatigue subgroup.
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Figure 2. Pain and Fatigue Subgroups Based on the Most Likely (expected a posteriori) Subgroup Membership of Each Respondent  
 
             Time 1                                                         Time 2 
 
Note: Intensity of each symptom is raw score and patients are classified based on the estimated model; The ranges of scores for fatigue and pain 
were 1–10; Higher scores indicated more intense symptoms. 
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Table 4. Odds Ratios and 95% Confidence Interval for Influencing Variables of Subgroup Membership 
 Time 1(n = 276)a Time 2 (n = 276) 
Comparison versus reference HPHF vs. LPLF LPHF vs. LPLF HPHF vs. LPHF HPHF vs. LPLF 
Site A 6.57 (0.70, 61.33) 9.04 (0.86, 94.64) 0.73 (0.24, 2.22)  4.44 (0.50, 39.81) 
Site B  7.69 (0.83, 71.14) 7.38 (0.71,76.12) 1.04 (0.30, 3.69) 3.09 (0.25, 38.57) 
Age 0.77 (0.50, 1.16) 0.83 (0.53,1.29) 0.93 (0.69, 1.26) 0.96 (0.58, 1.58) 
Cancer type (breast vs. others) 1.94 (0.47,8.11) 4.78 (0.98, 23.24) 0.41 (0.17,0.94) 1.45 (0.37, 5.68) 
Disease stage  
(stage I &II vs.III &IV) 
0.96 (0.48, 1.91) 1.02 (0.48, 2.15) 0.94 (0.63, 1.41) 1.74 (0.96,3.16 ) 
Comorbid-arthritis 2.69 (0.59, 12.30) 1.94 (0.28, 13.37) 1.39 (0.44, 4.21) 3.30 (0.45, 24.01) 
Comorbid- hypertension 0.72 (0.17,3.06) 0.64 (0.11,3.62) 1.13 (0.50, 2.60) 5.29 (1.49, 18.84)* 
Hemoglobin level 0.92 (0.59,1.43) 0.93 (0.57,1.51) 0.99 (0.81, 1.21) 0.87 (0.61, 1.23) 
Previous surgery (yes vs.no) 1.64 (0.40,6.61) 2.89 (0.61,13.70) 0.56 (0.24, 1.30) 0.72 (0.14, 3.47) 
Depressed mood 57.89 (6.59, 509.09)*** 67.22 (7.72, 585.13)*** 0.86 (0.56, 1.33) 4.33 (1.82, 10.26)** 
Time lapse since the first CTX (43–46 vs. 57–60 day) 0.14 (0.04, 0.47)** 
Symptom managementb (yes vs.no) 1.45 (0.52, 4.02) 
Employment statusc (employed vs. un-employed) 1.26 (0.40, 3.96) 
Note. aBonferroni correction was done for multiple comparisons. bAt Time 1, the intervention was not given and thus this variable was not entered in the model at 
Time 1. c Employment status interacted with the intervention effect on the secondary outcome of pain at Time 2 in the parent study and thus, this variable was 
included in the model at Time 2 model estimation; HPHF = high pain and high fatigue subgroup; LPLF = low pain and low fatigue subgroup; LPHF = low pain and 
high fatigue subgroup; *p < .05. **p < .01. ***p < .0001. An odds ratio >1 would mean that the higher-coded category (or higher values in a continuous variable) 
was associated with the greater odds of being in a given subgroup as opposed to the reference subgroup. A p-value < .05 indicated that the effect of a variable was 
significant after controlling for the rest of the variables in a model.
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Table 5. Differences in Functional Limitations by Subgroup at Each Time Point 
(N = 276) 
 Time 1 Mean (SD) 
Total 
(n = 276) 
HPHF 
(n = 114, 41.2%) 
LPHF 
(n = 90, 34.3%)) 
LPLF 
(n = 68, 24.5%) 
Overall test 
X2 (df=2) = 137.39 
(p < .0001) 
Functional limitations 5.36 (.22) 4.33 (.36) 1.49 (1.19 ) All p < .01 (df = 1)a 
 Time 2 Mean (SD) 
Total 
(n = 276 ) 
HPHF 
(n = 101, 36.5%) 
LPLF 
(n = 175, 63.5%) 
X2 (df=1) = 39.05 
(p < .0001) 
Functional limitations 5.21(0.28) 3.02(0.19)  
a Bonferroni correction was performed for multiple comparisons; HPHF = high pain and high fatigue subgroup; 
LPLF = low pain and low fatigue subgroup; LPHF = low pain and high fatigue subgroup. 
23 
 
References 
1. Oncology Nursing Society. 2009-2013 ONS research agenda. 2009. Available 
from http://www.ons.org/media/ons/docs/research. Retrieved November 20, 2010, 
2. Plante GE, VanItallie TB. Opioids for cancer pain: the challenge of optimizing 
treatment. Metabolism. 2010;59 Suppl 1:S47-52. 
3. Cella D, Davis K, Breitbart W, Curt G. Fatigue Coalition. Cancer-related fatigue. 
J Clin Oncol: prevalence of proposed diagnostic criteria in a United States sample 
of cancer survivors. 2001;19(14):3385-3391 
4. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, & Morrow GR. 
Cancer-related fatigue: the scale of the problem. Oncologist 2007;12 Suppl 1:4-10 
5. Torvinen S, Färkkilä N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related 
quality of life in prostate cancer. Acta Oncol. [Epub ahead of print]. 2013. 
6. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept 
analysis and clinical implications for cancer nursing. Cancer Nurs. 
2005;28(4):270-282; quiz 283-274. 
7. Chen ML, Lin CC. Cancer symptom clusters: a validation study. J Pain Symptom 
Manage. 2007;34(6):590-599. 
8. Kim HJ, Barsevick AM, Tulman L, McDermott PA. Treatment-related symptom 
clusters in breast cancer: a secondary analysis. J Pain Symptom Manage. 
2008;36(5):468-479. 
9. Wang SY, Tsai CM, Chen BC, Lin CH, Lin CC. Symptom clusters and 
relationships to symptom interference with daily life in Taiwanese lung cancer 
patient. J Pain Symptom Manage. 2008;35(3):258-266 
24 
 
10. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and 
quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 
2010;33(1):3-10. 
11. Walsh D, Rybicki L. Symptom clustering in advanced cancer. Support Care 
Cancer. 2006;14(8):831-836 
12. Kim HJ, Barsevick AM, Beck SL, Dudley W. Clinical subgroups of a 
psychoneurologic symptom cluster in women receiving treatment for breast 
cancer: a secondary analysis. Oncol Nurs Forum. 2012;39(1):E20-30. 
13. Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer 
with different symptom experiences and quality-of-life outcomes: a cluster 
analysis. Oncol Nurs Forum. 2006;33(5):E79-89. 
14. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology 
outpatients has a different impact on quality-of-life outcomes. J Pain Symptom 
Manage. 2008;35(2):162-170 
15. Kozachik SL, Bandeen-Roche K. Predictors of patterns of pain, fatigue, and 
insomnia during the first year after a cancer diagnosis in the elderly. Cancer Nurs. 
2008;31(5): 334-344. 
16. Given CW, Given B, Azzouz F, Kozachik S, Stommel M. Predictors of pain and 
fatigue in the year following diagnosis among elderly cancer patients. J Pain 
Symptom Manage. 2001;21(6):456-466. 
17. Chung H, Flaherty BP, Schafer JL. Latent-class logistic regression. J R Stat Series 
A: Application to marijuana use and attitudes among high-school seniors. 
2006;169:723-743 
25 
 
18. Wade TD, Crosby RD, Martin NG. Use of latent profile analysis to identify eating 
disorder phenotypes in an adult Australian twin cohort. Arch Gen Psychiatry. 
2006;63(12):1377-1384 
19. Kim HJ, Abraham I, Malone PS. Analytical methods and issues for symptom 
cluster research in oncology. Curr Opin Support Palliat Care. 2013;7(1):45-53 
20. Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: A SAS Procedure 
for Latent Class Analysis. Struct Equ Modeling. 2007;14(4):671-694. 
21. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of 
unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997;19(3):14-27. 
22. Geinitz H, Zimmermann FB, Thamm R, Keller M, Busch R, Molls M. Fatigue in 
patients with adjuvant radiation therapy for breast cancer. J Cancer Res Clin 
Oncol: long-term follow-up. 2004;130(6):327-333 
23. Barsevick A, Beck SL, Dudley WN, et al. Efficacy of an intervention for fatigue 
and sleep disturbance during cancer chemotherapy. J Pain Symptom Manage. 
2010;40(2):200-216. 
24. Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer 
chemotherapy. Oncol Nurs Forum. 1998;25(1):51-62. 
25. Meek PM, Nail LM, Barsevick A, et al. Psychometric testing of fatigue 
instruments for use with cancer patients. Nurs Res. 2000;49(4):181-190. 
26. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. 
Ann Acad Med Singapore. 1994;23(2):129-138 
27. McGuire DB, Kim HJ, Lang X. Measuring pain. In: Frank-stromborg M. & Olsen 
S.J. (EDS.) Instruments for Clinical Health-Care Research.3rd ed. Sudbury 
Massachusetts: Jones and Bartlett Publishers.2004:603-644 
26 
 
28. Meek PNLJL. Internal consistency reliability and construct validity of a new 
measure of cancer treatment related fatigue: the General Fatigue Scale (GFS). 
Oncol Nurs Forum. 1997;24(2):334. 
29. McNair DMLMDL. Profile of mood states (Revised ed.). San Diego, CA 
Educational and Industrial Testing Service. 1981 
30. Akaike H. A new look at the statistical mode identification. IEEE Trans Automat 
Contr. 1974;19:716-723 
31. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-464 
32. Gift AG, Jablonski A, Stommel M, Given CW. Symptom clusters in elderly 
patients with lung cancer. Oncol Nurs Forum. 2004;31(2):202-212. 
33. Gwede CK, Small BJ, Munster PN, Andrykowski MA, Jacobsen PB. Exploring 
the differential experience of breast cancer treatment-related symptoms: a cluster 
analytic approach. Support Care Cancer. 2008;16(8):925-933. 
34. Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti- 
inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep 
disturbance, and depression. Cytokine. 2012;58(3):437-447 
